NCT02669589

Investigating Different Anticoagulants for Renal Replacement Therapy

Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 638 (actual)
• Sponsor: University Hospital Muenster · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the effect of regional citrate anticoagulation within the scope of continuous renal replacement (CRRT) in critically ill patients with acute kidney injury (AKI) on filter life span and 90-day all cause mortality.

Detailed description

Purpose of clinical trial: To evaluate the effect of regional citrate anticoagulation within the scope of continuous renal replacement (CRRT) in critically ill patients with acute kidney injury (AKI) on filter life span and 90-day all cause mortality. Patient population: critically ill patients with acute kidney injury requiring renal replacement therapy. Primary objective: Anticoagulation of the extracorporeal circuit is required in continuous RRT (CRRT). To this date, it is not clear which anticoagulant should be used for CRRT. Regional citrate anticoagulation (RCA) for CRRT in critically ill patients with AKI prolongs filter life span and reduces 90-day all cause mortality by approximately 8% (from 48% to 40%) compared to systemic heparin anticoagulation for CRRT

Conditions

• Acute Kidney Injury

Interventions

Type	Name	Description
DRUG	Heparin
DRUG	Citrate

Timeline

• Start date: 2016-03-01
• Primary completion: 2019-04-03
• Completion: 2020-01-03
• First posted: 2016-02-01
• Last updated: 2020-02-19

Locations

31 sites across 1 country: Germany